Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort

Shannon L Risacher1, Andrew J Saykin, John D West

  • 1IU Center for Neuroimaging, Division of Imaging Sciences, Department of Radiology, Indiana University School of Medicine, 950 W Walnut St, R2 E124, Indianapolis, IN 46202, USA.

Insights

Neuroimaging reveals that medial temporal lobe atrophy, particularly reduced hippocampal volume, predicts imminent Alzheimer's disease (AD) conversion in Mild Cognitive Impairment (MCI) patients. This finding aids in identifying high-risk individuals for clinical trials.

Area of Science:

  • Neuroimaging
  • Neurology
  • Biomarker Discovery

Background:

  • Alzheimer's Disease Neuroimaging Initiative (ADNI) studies neuroimaging for diagnosis and monitoring.
  • Amnestic Mild Cognitive Impairment (MCI) is a prodromal stage of dementia with a significant annual risk of progressing to Alzheimer's Disease (AD).

Purpose of the Study:

  • To identify neuroimaging phenotypes associated with MCI and AD.
  • To discover potential predictive markers for imminent conversion from MCI to AD using MRI.
  • To analyze structural MRI changes in relation to cognitive status and conversion over one year.

Main Methods:

  • Analysis of baseline 1.5T MRI scans from 693 participants in the ADNI cohort.
  • Categorization of participants into healthy controls (HC), MCI, and AD groups, with further division of MCI into converters and stable groups.
  • Utilized voxel-based morphometry (VBM) and automated parcellation to assess grey matter density, volumes (hippocampus, amygdala), and cortical thickness.

Main Results:

  • Structural MRI changes in MCI and AD mirrored previous findings.
  • MCI converters showed similar atrophy patterns to AD patients up to a year prior to diagnosis.
  • Medial temporal lobe degeneration, especially decreased hippocampal volume (left > right), was the strongest MRI marker for imminent MCI to AD conversion.

Conclusions:

  • Reduced hippocampal volume is a robust neuroimaging biomarker for predicting imminent conversion from MCI to AD.
  • Neuroimaging markers can facilitate the enrichment of clinical trials for disease-modifying agents by identifying at-risk populations.
  • Validation of imaging biomarkers is crucial for advancing AD therapeutic development.